Literature DB >> 21359967

Expression and functional properties of canine, rat, and murine histamine H₄ receptors in Sf9 insect cells.

David Schnell1, Irena Brunskole, Katerina Ladova, Erich H Schneider, Patrick Igel, Stefan Dove, Armin Buschauer, Roland Seifert.   

Abstract

The histamine H₄ receptor (H₄R) is expressed on cells of the immune system including eosinophils, dendritic cells, and T cells and plays an important role in the pathogenesis of bronchial asthma, atopic dermatitis, and pruritus. Analysis of the H₄R in these diseases depends on the use of animal models. However, there are substantial pharmacological differences between various H₄R species orthologs. The purpose of this study was to analyze the pharmacological properties of canine, rat, and murine H₄R in comparison to human H₄R expressed in Sf9 insect cells. Only hH₄R and cH₄R exhibited a sufficiently high [³H]histamine affinity for radioligand binding studies. Generally, cH₄R exhibited lower ligand-affinities than hH₄R. Similarly, in high-affinity GTPase studies, ligands were more potent at hH₄R than at other H₄R species orthologs. Unlike the other H₄R species orthologs, hH₄R exhibited high agonist-independent (constitutive) activity. Most strikingly, the prototypical H₄R antagonist (1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine) (JNJ7777120) exhibited partial agonistic activity at cH₄R, rH₄R, and mH₄R, whereas at hH₄R, JNJ7777120 was a partial inverse agonist. H₄R agonists from the class of N ( G )-acylated imidazolylpropylguanidines and cyanoguanidines exhibited substantial differences in terms of affinity, potency, and efficacy among H₄R species orthologs, too. The species-dependent pharmacological profiles are not due to the highly variable amino acid sequence position 341. Finally, H₄R species orthologs differ from each other in terms of regulation by NaCl. Collectively, there are profound pharmacological differences between H₄R species orthologs. Most importantly, caution must be exerted when interpreting pharmacological effects of "the prototypical H₄R antagonist" JNJ7777120 as H₄R antagonism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21359967     DOI: 10.1007/s00210-011-0612-3

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  53 in total

Review 1.  Molecular and biochemical pharmacology of the histamine H4 receptor.

Authors:  Rob Leurs; Paul L Chazot; Fiona C Shenton; Herman D Lim; Iwan J P de Esch
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

2.  Distinct interaction of human and guinea pig histamine H2-receptor with guanidine-type agonists.

Authors:  M T Kelley; T Bürckstümmer; K Wenzel-Seifert; S Dove; A Buschauer; R Seifert
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

3.  Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions.

Authors:  T Costa; J Lang; C Gless; A Herz
Journal:  Mol Pharmacol       Date:  1990-03       Impact factor: 4.436

4.  High constitutive activity of the human formyl peptide receptor.

Authors:  K Wenzel-Seifert; C M Hurt; R Seifert
Journal:  J Biol Chem       Date:  1998-09-11       Impact factor: 5.157

Review 5.  The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines.

Authors:  Robin L Thurmond; Erwin W Gelfand; Paul J Dunford
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

6.  Cationic-amphiphilic arpromidine-derived guanidines and a histamine trifluoromethyl-toluidide derivative may activate pertussis toxin-sensitive G-proteins by a receptor-independent mechanism.

Authors:  A Hagelüken; R Burde; B Nürnberg; R Harhammer; A Buschauer; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-03       Impact factor: 3.000

7.  In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties.

Authors:  M I Strakhova; C A Cuff; A M Manelli; T L Carr; D G Witte; J L Baranowski; T A Vortherms; T R Miller; L Rundell; M J McPherson; R M Adair; A A Brito; B M Bettencourt; B B Yao; J M Wetter; K C Marsh; H Liu; M D Cowart; J D Brioni; T A Esbenshade
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

8.  Histamine H(4) receptor-RGS fusion proteins expressed in Sf9 insect cells: a sensitive and reliable approach for the functional characterization of histamine H(4) receptor ligands.

Authors:  Erich H Schneider; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2009-05-21       Impact factor: 5.858

9.  High constitutive activity and a G-protein-independent high-affinity state of the human histamine H(4)-receptor.

Authors:  Erich H Schneider; David Schnell; Dan Papa; Roland Seifert
Journal:  Biochemistry       Date:  2009-02-17       Impact factor: 3.162

10.  Impact of the DRY motif and the missing "ionic lock" on constitutive activity and G-protein coupling of the human histamine H4 receptor.

Authors:  Erich H Schneider; David Schnell; Andrea Strasser; Stefan Dove; Roland Seifert
Journal:  J Pharmacol Exp Ther       Date:  2010-01-27       Impact factor: 4.030

View more
  19 in total

1.  Commercially available antibodies against human and murine histamine H₄-receptor lack specificity.

Authors:  Silke Beermann; Roland Seifert; Detlef Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-10       Impact factor: 3.000

2.  Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics.

Authors:  Heidrun Appl; Tobias Holzammer; Stefan Dove; Ekkehard Haen; Andrea Strasser; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-28       Impact factor: 3.000

Review 3.  Inhibitors of membranous adenylyl cyclases.

Authors:  Roland Seifert; Gerald H Lushington; Tung-Chung Mou; Andreas Gille; Stephen R Sprang
Journal:  Trends Pharmacol Sci       Date:  2011-11-17       Impact factor: 14.819

4.  Role of the second and third extracellular loops of the histamine H(4) receptor in receptor activation.

Authors:  Irena Brunskole; Andrea Strasser; Roland Seifert; Armin Buschauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-29       Impact factor: 3.000

5.  Molecular determinants for the high constitutive activity of the human histamine H4 receptor: functional studies on orthologues and mutants.

Authors:  D Wifling; K Löffel; U Nordemann; A Strasser; G Bernhardt; S Dove; R Seifert; A Buschauer
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

6.  The dual H3/4R antagonist thioperamide does not fully mimic the effects of the 'standard' H4R antagonist JNJ 7777120 in experimental murine asthma.

Authors:  Detlef Neumann; Silke Beermann; Heike Burhenne; Silke Glage; Christina Hartwig; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-07-03       Impact factor: 3.000

Review 7.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

8.  Differential effects of functionally different histamine H4 receptor ligands on acute irritant dermatitis in mice.

Authors:  Maristella Adami; Cristina Micheloni; Daniela Grandi; Holger Stark
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-25       Impact factor: 3.000

9.  Synthesis, biological evaluation, and computational studies of Tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and hH3 receptor antagonists.

Authors:  Fouad H Darras; Steffen Pockes; Guozheng Huang; Sarah Wehle; Andrea Strasser; Hans-Joachim Wittmann; Martin Nimczick; Christoph A Sotriffer; Michael Decker
Journal:  ACS Chem Neurosci       Date:  2014-01-14       Impact factor: 4.418

10.  Histamine H4-receptors inhibit mast cell renin release in ischemia/reperfusion via protein kinase C ε-dependent aldehyde dehydrogenase type-2 activation.

Authors:  Silvia Aldi; Ken-ichi Takano; Kengo Tomita; Kenichiro Koda; Noel Y-K Chan; Alice Marino; Mariselis Salazar-Rodriguez; Robin L Thurmond; Roberto Levi
Journal:  J Pharmacol Exp Ther       Date:  2014-04-02       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.